Immuneering (NASDAQ:IMRX) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Immuneering (NASDAQ:IMRX) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts have also commented on IMRX. Needham & Company LLC upped their target price on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, September 21st. UBS Group set a $14.00 target price on shares of Immuneering in a report on Thursday, August 6th. Chardan Capital raised shares of Immuneering to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, Mizuho set a $11.00 target price on Immuneering in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immuneering has an average rating of “Moderate Buy” and a consensus target price of $15.67.

Immuneering Trading Up 9.2%

IMRX opened at $3.68 on Friday. The firm has a market cap of $238.32 million, a price-to-earnings ratio of -3.57 and a beta of 0.49. Immuneering has a 12 month low of $3.35 and a 12 month high of $8.48. The stock has a fifty day moving average price of $4.12 and a 200-day moving average price of $4.77.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.06). On average, equities research analysts forecast that Immuneering will post -1.19 EPS for the current year.

Institutional Trading of Immuneering

A number of hedge funds and other institutional investors have recently bought and sold shares of IMRX. Aberdeen Group plc purchased a new stake in shares of Immuneering in the third quarter valued at approximately $3,214,000. Fisher Asset Management LLC increased its stake in Immuneering by 31.3% in the 3rd quarter. Fisher Asset Management LLC now owns 115,954 shares of the company’s stock valued at $475,000 after buying an additional 27,621 shares during the period. Alps Advisors Inc. grew its position in Immuneering by 29.6% in the third quarter. Alps Advisors Inc. now owns 85,109 shares of the company’s stock valued at $349,000 after acquiring an additional 19,451 shares during the period. Principle Wealth Partners LLC bought a new stake in Immuneering in the third quarter valued at approximately $51,000. Finally, VestGen Advisors LLC raised its stake in Immuneering by 100.0% in the 3rd quarter. VestGen Advisors LLC now owns 20,002 shares of the company’s stock valued at $82,000 after acquiring an additional 10,002 shares during the period. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.